HUE053296T2 - TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése során - Google Patents
TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése soránInfo
- Publication number
- HUE053296T2 HUE053296T2 HUE16744353A HUE16744353A HUE053296T2 HU E053296 T2 HUE053296 T2 HU E053296T2 HU E16744353 A HUE16744353 A HU E16744353A HU E16744353 A HUE16744353 A HU E16744353A HU E053296 T2 HUE053296 T2 HU E053296T2
- Authority
- HU
- Hungary
- Prior art keywords
- proliferative
- treatment
- inflammatory disorders
- tfr antibodies
- tfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192 | 2015-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053296T2 true HUE053296T2 (hu) | 2021-06-28 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16744353A HUE053296T2 (hu) | 2015-07-22 | 2016-07-21 | TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése során |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (hu) |
| EP (1) | EP3325509B1 (hu) |
| JP (1) | JP6858185B2 (hu) |
| KR (1) | KR102690998B1 (hu) |
| CN (1) | CN107849136B (hu) |
| AU (1) | AU2016296321B2 (hu) |
| BR (1) | BR112018000650A2 (hu) |
| CA (1) | CA2992509A1 (hu) |
| CY (1) | CY1123941T1 (hu) |
| DK (1) | DK3325509T3 (hu) |
| ES (1) | ES2860988T3 (hu) |
| HK (1) | HK1256088A1 (hu) |
| HR (1) | HRP20210393T1 (hu) |
| HU (1) | HUE053296T2 (hu) |
| IL (1) | IL257065B (hu) |
| LT (1) | LT3325509T (hu) |
| MX (1) | MX2018000569A (hu) |
| PL (1) | PL3325509T3 (hu) |
| PT (1) | PT3325509T (hu) |
| RS (1) | RS61586B1 (hu) |
| RU (1) | RU2737637C2 (hu) |
| SI (1) | SI3325509T1 (hu) |
| SM (1) | SMT202100134T1 (hu) |
| WO (1) | WO2017013230A1 (hu) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3292149T (lt) | 2015-05-04 | 2022-03-10 | Cytomx Therapeutics, Inc. | Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| EA202190416A1 (ru) | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2021092482A1 (en) * | 2019-11-06 | 2021-05-14 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| KR20220134584A (ko) * | 2020-01-31 | 2022-10-05 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
| US11969475B2 (en) * | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11638761B2 (en) * | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2024534880A (ja) | 2021-09-01 | 2024-09-26 | バイオジェン・エムエイ・インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用 |
| WO2023039611A2 (en) * | 2021-09-13 | 2023-03-16 | The Board Of Regents Of The University Of Texas System | Tfr antigen binding proteins and uses thereof |
| AU2023254846A1 (en) * | 2022-04-15 | 2024-10-10 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| WO2024114687A1 (en) * | 2022-12-02 | 2024-06-06 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-tfr1 antibodies and uses thereof |
| TW202444759A (zh) | 2023-03-24 | 2024-11-16 | 美商戴納立製藥公司 | Ａβ靶向蛋白及使用方法 |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| MX353234B (es) * | 1999-01-15 | 2018-01-08 | Genentech Inc | Variantes de polipeptidos con función efectora alterada. |
| HUE027549T2 (hu) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| PT1740616E (pt) * | 2004-04-30 | 2012-03-23 | Inst Nat Sante Rech Med | Anticorpo anti-rtf |
| CN101432305B (zh) * | 2004-06-07 | 2014-07-30 | 雷文生物技术公司 | 运铁蛋白受体抗体 |
| AU2006244885B2 (en) * | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| FR2953841B1 (fr) * | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| US20150197574A1 (en) * | 2012-08-02 | 2015-07-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
| CN104797600A (zh) * | 2012-11-08 | 2015-07-22 | 国立大学法人宫崎大学 | 能够特异性识别转铁蛋白受体的抗体 |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 BR BR112018000650A patent/BR112018000650A2/pt active Search and Examination
- 2016-07-21 CA CA2992509A patent/CA2992509A1/en active Pending
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en active Application Filing
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
-
2018
- 2018-11-27 HK HK18115150.4A patent/HK1256088A1/zh unknown
-
2021
- 2021-03-08 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053296T2 (hu) | TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése során | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| IL262092A (en) | Humanized anti-pacap antibodies and uses thereof | |
| HK1258058A1 (zh) | 抗tigit抗體和使用方法 | |
| IL256687B (en) | Isolated tau-binding antibody and its use in treatment and diagnosis | |
| HUE052771T2 (hu) | C10orf54 elleni antitestek és alkalmazásuk | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| HUE066591T2 (hu) | 8-ciano-5-piperidino-kinolinok, mint TLR7/8 antagonisták és alkalmazásuk immunrendellenességek kezelésére | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| HUE061253T2 (hu) | Antitestek OX40 ellen és azok felhasználásai | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| HUE062189T2 (hu) | Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| SMT202400477T1 (it) | Anticorpi tetravalenti bispecifici e loro procedimenti di fabbricazione e d'uso | |
| HUE061576T2 (hu) | Kevert allergén készítmények és eljárások alkalmazásukra | |
| HUE055233T2 (hu) | Az EGFR gátló és annak elkészítése és alkalmazása | |
| BR112016021626A2 (pt) | indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas | |
| PT2953969T (pt) | Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios | |
| HK1255312A1 (zh) | 抗原受體及其用途 | |
| HUE036084T2 (hu) | Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél | |
| HUE054093T2 (hu) | Anti-HtrA1 antitestek és azok alkalmazási eljárásai | |
| LT3532499T (lt) | Antikūnai prieš il-33 ir jų panaudojimas | |
| HUE052223T2 (hu) | IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként |